Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists

Curr Oncol. 2021 Nov 16;28(6):4748-4755. doi: 10.3390/curroncol28060400.

Abstract

Background: Despite successes in the development of innovative anticancer therapies, the fiscal and capacity restraints of the Canadian public healthcare system result in challenges with drug access. A meaningful proportion of systemic therapies ultimately do not receive public funding despite supporting clinical evidence. In this study, we assessed Canadian medical oncologists' current attitudes toward discussing publicly unfunded cancer treatments with patients and predictors of different practices.

Methods: A web-based survey consisting of multiple choice and case-based scenarios was distributed to medical oncologists identified through the Royal College of Physicians and Surgeons of Canada directory.

Results: A total of 116 responses were received. Almost all respondents reported discussing publicly unfunded treatments, including those who did so for Health Canada (HC) approved treatments (50%) and those who discussed off-label treatments (i.e., not HC approved) as guided by national guidelines (48%). Respondents in practice for over 15 years versus less than 5 years (OR 0.14, 95% CI 0.04-0.50, p = 0.002) and those who worked in a community practice versus comprehensive cancer center (OR 0.17, 95% CI 0.03-0.91, p = 0.04) were significantly less likely to discuss off-label treatment options with their patients. Almost half of respondents (47%) indicated that their institution did not permit the administration of unfunded treatments.

Conclusions: There is variability in medical oncologists' practices when it comes to discussing unfunded therapies. Given the limitations within Canada's publicly funded healthcare system, physicians are faced with the challenge of navigating an increasingly complex balance between patient care and available resources. Engagement of relevant stakeholders and policy makers is crucial in the continued evaluation of Canada's drug funding process.

Keywords: Canadian; medical oncology; unfunded cancer therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / economics
  • Antineoplastic Agents* / therapeutic use
  • Attitude
  • Attitude of Health Personnel*
  • Canada
  • Health Care Surveys
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Internet
  • Neoplasms* / drug therapy
  • Oncologists*
  • Single-Payer System / economics
  • Therapies, Investigational / economics

Substances

  • Antineoplastic Agents

Grants and funding